SCHEMBL20045103

SCHEMBL20045103

Cc1cccc(CC(=O)O)c1CN

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 4/20 0.51
AKR1B1 P15121 2/20 0.46
TDP1 Q9NUW8 1/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
SLC22A12 Q96S37 2/20 0.43
PTGS1 P23219 1/20 0.41
GLA P06280 1/20 0.41
STING1 Q86WV6 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
CTBP2 P56545 1/20 0.40
DUSP3 P51452 1/20 0.40
PTPN5 P54829 1/20 0.40
PTPN11 Q06124 1/20 0.40
CTDSP1 Q9GZU7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7911305 0.87 PTGS2 (0.56) PTGS2AKR1B1TDP1KDM4EMEN1
SCHEMBL20045094 0.84 PTGS2 (0.56) PTGS2AKR1B1TDP1KDM4EMEN1
SCHEMBL869978 0.82 PTGS2 (0.51) PTGS2AKR1B1TDP1KDM4EMEN1
Methylamine SCHEMBL11468456 0.81 CTBP2 (0.58) PTGS2AKR1B1TDP1KDM4EMEN1
Methylamine SCHEMBL11484609 0.79 CTBP2 (0.56) PTGS2AKR1B1TDP1KDM4EMEN1
SCHEMBL3860562 0.79 TAAR1 (0.43) PTGS2CYP2C9CYP2C19
SCHEMBL1004574 0.78 KDM4E (0.58) PTGS2AKR1B1KDM4EMEN1GAA
SCHEMBL3670971 0.78 TAAR1 (0.46)
SCHEMBL23241554 0.78 AKR1B1 (0.48) PTGS2AKR1B1TDP1KDM4EMAPT
SCHEMBL16396968 0.78 PTGS2 (0.54) PTGS2AKR1B1TDP1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180098952-A1 INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA NORTHWESTERN UNIVERSITY (US) 2018-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180098952-A1 INACTIVATORS OF TOXOPLASMA GONDII ORNITHINE AMINOTRANSFERASE FOR TREATING TOXOPLASMOSIS AND MALARIA OAT, OTC, ABAT PTGS2 1138/4885AKR1B1 225/4885TDP1 1275/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.